1. Home
  2. AVAH vs URGN Comparison

AVAH vs URGN Comparison

Compare AVAH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aveanna Healthcare Holdings Inc.

AVAH

Aveanna Healthcare Holdings Inc.

N/A

Current Price

$12.30

Market Cap

2.7B

Sector

Health Care

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$26.27

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AVAH
URGN
Founded
1984
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.2B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
AVAH
URGN
Price
$12.30
$26.27
Analyst Decision
Buy
Strong Buy
Analyst Count
11
7
Target Price
$15.05
★ $60.71
AVG Volume (30 Days)
★ 1.9M
1.2M
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1850.00
N/A
EPS
★ 0.57
N/A
Revenue
★ $2,433,199,000.00
$1,128,000.00
Revenue This Year
$10.70
$190.44
Revenue Next Year
$7.63
$69.25
P/E Ratio
$22.90
★ N/A
Revenue Growth
★ 20.19
N/A
52 Week Low
$5.93
$16.50
52 Week High
$14.71
$50.81

Technical Indicators

Market Signals
Indicator
AVAH
URGN
Relative Strength Index (RSI) 40.70 29.46
Support Level $12.21 $22.61
Resistance Level $13.76 $27.76
Average True Range (ATR) 0.67 2.03
MACD -0.07 -0.45
Stochastic Oscillator 8.54 20.19

Price Performance

Historical Comparison
AVAH
URGN

About AVAH Aveanna Healthcare Holdings Inc.

Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: